Asundexian Phase 3 AF Study Halted for Lack of Efficacy ...Middle East

Medscape - News
The phase 3 OCEANIC-AF trial of the factor XI inhibitor asundexian (Bayer) has been stopped early owing to inferior efficacy vs apixaban in preventing stroke and systemic embolism in patients with AF. Medscape Medical News

Hence then, the article about asundexian phase 3 af study halted for lack of efficacy was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Asundexian Phase 3 AF Study Halted for Lack of Efficacy )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News


Latest News